Semax: Nootropic Peptide Research Overview

September 28, 2026 · By My Store 3 Admin

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH). Originally developed in Russia in the 1980s by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, it has been studied primarily in the context of neuroprotection, cognitive function, and neuroplasticity. Unlike many peptide research compounds in Western literature, Semax has an established history of use in clinical and hospital settings in Russia and some Eastern European countries, though it is not approved by the MHRA, EMA, or FDA as a therapeutic agent.

This article provides a research-focused overview of Semax’s molecular profile, proposed mechanisms, and published research. All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Molecular Profile

Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro, representing the 4–10 fragment of ACTH with a Pro-Gly-Pro C-terminal extension that confers resistance to enzymatic degradation and extends biological activity compared to the native ACTH fragment. The compound is water-soluble and stable in lyophilised form.

It is structurally distinct from the full ACTH peptide (39 amino acids) and does not share ACTH’s adrenal-stimulating activity — the fragment retains only the proposed cognitive and neuroprotective properties attributed to the 4–10 region, without corticotropin receptor agonism.

Proposed Mechanisms

BDNF and NGF upregulation — perhaps the most studied proposed mechanism; preclinical and some clinical research has reported that Semax increases the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Both neurotrophins play key roles in neuroplasticity, neuron survival, and synaptic function.
Melanocortin receptor interaction — the ACTH 4–10 core sequence has affinity for melanocortin receptors (particularly MC4R and MC5R in the CNS), which have been implicated in learning, memory, and attentional processes.
Neuroprotective effects — rodent studies have investigated Semax in models of stroke, ischaemia, and neurodegeneration, proposing effects on oxidative stress, inflammation, and neuronal apoptosis.
Dopaminergic and serotonergic modulation — some research has proposed interactions with monoaminergic neurotransmitter systems, though mechanistic characterisation in this area is less developed.

Areas of Preclinical and Clinical Research

Cognitive function and memory in healthy and impaired rodent models
Neuroprotection in ischaemic stroke models
Attention and learning performance
Neurotrophin (BDNF, NGF) expression modulation
Stress adaptation and anxiolytic effects in animal models
Early-phase clinical investigation in Russia for stroke, optic nerve atrophy, and cognitive impairment (small studies; not peer-reviewed in Western journals to the same standard)

Evidence Landscape

The Semax literature has a distinctive character that researchers should understand:

Origin concentration — the majority of published research originated in Russian institutions, limiting independent Western replication. The compound is not widely studied in Western academic laboratories.
Clinical use without Western clinical trials — Semax has been used in clinical settings in Russia for conditions including stroke and cognitive decline; however, these clinical applications predate or operate outside the randomised controlled trial framework standard in Western regulatory contexts.
Preclinical evidence — rodent models consistently report positive effects on cognitive and neuroprotective endpoints, but translational reliability from rodent to human CNS outcomes is generally considered lower than for peripheral tissue endpoints.
BDNF mechanism — the BDNF upregulation hypothesis is supported by multiple independent studies and represents the most mechanistically characterised and independently replicated proposed effect of Semax.

Semax vs Selank

Semax and Selank are the two principal nootropic peptide research compounds developed from Russian research programmes. Both operate via proposed central nervous system mechanisms, but with distinct primary profiles:

Semax — proposed stimulatory and cognitive-enhancing effects; primary mechanism involves BDNF/NGF upregulation and melanocortin receptor interaction
Selank — proposed anxiolytic and anti-stress effects; primary mechanism involves the enkephalin system and GABA modulation

For a full overview of Selank, see: Selank: Anxiolytic Peptide Research Overview.

UK Research Context

Semax is not classified as a controlled substance in the UK and is available as a research material for in vitro laboratory use. Researchers should refer to the UK regulatory framework for research peptides for the relevant legislative context, and should verify the current regulatory status for their specific research application.

Research Material

Bloom Vitality supplies Semax 10mg as a lyophilised research compound, independently third-party tested for purity and potency. Our Semax research material is part of the broader research peptides UK catalogue. Batch-specific Certificates of Analysis are available via our Certificates & Documentation page and Testing & Quality page.